FHIM 2026: showcasing European healthcare in Shanghai
For hospitals, pharmaceutical and med tech companies, investors and healthcare organisations across Asia, FHIM (Future Healthcare Investment Market) 2026, to be held 4–5 November 2026. provides a focused platform to engage with European healthcare institutions, procurement networks and investors, while also connecting with leading hospitals, innovation ecosystems and capital partners in China.
Confirmed procurement-side participants include Hirslanden, EHPPA, MercurHosp and XMED iQ, representing private hospital, public procurement, central purchasing and pan-European digital GPO networks.
For hospital groups and healthcare organisations across Asia, FHIM also creates opportunities to engage with leading hospitals and healthcare groups in China as well as public and private hospital networks in Europe, with potential cooperation spanning clinical practice, technology adoption, hospital operations, digital transformation and international partnerships.
For GPs and LPs across Asia, FHIM connects investors with European LPs, family offices, insurers, institutional investors and healthcare-focused capital, creating opportunities for fundraising, co-investment and long-term capital partnerships.
For investors seeking high-quality assets, FHIM also brings together companies and projects across pharma, med tech, digital health and healthcare services, providing direct exposure to potential investment and strategic cooperation opportunities.
For med tech companies, FHIM connects market access with clinical validation, hospital procurement, distribution and local partnerships. This is relevant both to Asian companies seeking entry into European healthcare systems and to European companies exploring adoption and commercial partnerships in China and wider Asia.
For pharma and biotech companies, FHIM connects business development teams from leading pharmaceutical companies and multinational corporations across Europe and China with investors, clinical partners and other industry decision-makers, creating opportunities for licensing, joint development, financing and international commercialisation.
The show is built on the combined strengths of IPEM (International Private Equity Market), HBI (Healthcare Business International) and a China-based network spanning government, healthcare institutions, investors, industry leaders and innovation partners.
(Press Release)
Category: Top Story
